Background: Extending the therapeutic window for thrombolysis is an important strategy in maximizing the proportion of patients treated. ECASS III examined a 3–4.5-hour window and showed a benefit to treated patients. We examined the experience in Canadian centres using intravenous tPA treatment in the 3–4.5-hour time window. Methods: The data were obtained from the CASES (Canadian Alteplase for Stroke Effectiveness Study) – a prospective, multicentric cohort study with patient enrollment from 60 centres across Canada over 2.5 years. The 90-day outcome, mortality and symptomatic intracranial hemorrhage of patients thrombolysed between 3 and 4.5 h and within 3 h of symptom onset were compared. A mRS 0–1 (no symptoms at all or no significant disability despite symptoms, able to carry out all usual duties and activities) at 90 days was defined as a favorable outcome. Results: A total of 1,112 patients with complete data were included. 129 (11.6%) patients received tPA between 3 and 4.5 h of symptom onset and 983 (88.4%) patients received tPA within 3 h. At 90 days, 39.4% of the patients in the 3–4.5-hour treatment group and 36.5% of patients in the under 3-hour treatment group attained a mRS ≤1. There were no differences between the two groups regarding their functional status at 3 months. There was a trend towards higher rate of sICH in the 3–4.5-hour group compared to the 0–3-hour group (7.8 vs. 3.8%, p = 0.06). Similarly there was a trend towards higher rate of deaths in the 3–4.5-hour group compared to the 0–3-hour group (28.4 vs. 21.4%, p = 0.09). A χ2 test for trend demonstrated a rising proportion of symptomatic ICH in later time windows (p = 0.013). A similar trend (non-significant) was observed for mortality. Conclusion: Our study suggests that patients with acute ischemic stroke may be successfully treated with intravenous tPA in the 3–4.5-hour treatment window, but cautions that later time window treatment may result in greater adverse events.

Keywords:
Alteplase, Thrombolysis, Symptomatic intracranial hemorrhage
1.
Lees KR, Bluhmki E, von Kummer R, et al: Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695–1703.
2.
Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, Roine RO, Toni D, Lees KR: Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303–1309.
3.
Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S: Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 h after symptom onset. The Atlantis Study: a randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA 1999;282:2019–2026.
4.
Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017–1025.
5.
Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European Australasian Acute Stroke Study investigators. Lancet 1998;352:1245–1251.
6.
Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S: Association of outcome with early stroke treatment: pooled analysis of Atlantis, Ecass, and NINDS rt-pa stroke trials. Lancet 2004;363:768–774.
7.
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D: Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med 2008;359:1317–1329.
8.
Wahlgren N: Systemic thrombolysis in clinical practice: what have we learned after the Safe Implementation of Thrombolysis in Stroke Monitoring Study? Cerebrovasc Dis 2009;27(suppl 1):168–176.
9.
Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, Parsons M, Roine RO, Toni D, Ringleb P, SITS Investigators: Implementation and outcome of thrombolysis with alteplase 3–4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866–874.
10.
Wardlaw JM, Murray V, Berge E, Del Zoppo GJ: Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; (4):CD000213.
11.
Hill MD, Buchan AM: Methodology for the canadian activase for stroke effectiveness study (cases): cases investigators. Can J Neurol Sci 2001;28:232–238.
12.
Hill MD, Buchan AM: Thrombolysis for acute ischemic stroke: results of the Canadian alteplase for stroke effectiveness study. CMAJ 2005;172:1307–1312.
13.
Barber PA, Demchuk AM, Zhang J, Buchan AM: Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS study group: Alberta stroke programme early CT score. Lancet 2000;355:1670–1674.
14.
Puetz V, Dzialowski I, Hill MD, Demchuk AM: The Alberta stroke program early CT score in clinical practice: what have we learned? Int J Stroke 2009;4:354–364.
15.
van den Berg JS, de Jong G: Why ischemic stroke patients do not receive thrombolytic treatment: results from a general hospital. Acta Neurol Scand 2009;120:157–160.
16.
Kleindorfer DO, Broderick JP, Khoury J, Flaherty ML, Woo D, Alwell K, Moomaw CJ, Pancioli A, Jauch E, Miller R, Kissela BM: Emergency department arrival times after acute ischemic stroke during the 1990s. Neurocrit Care 2007;7:31–35.
17.
Lindsay P, Bayley M, Hellings C, Hill MD, Woodbury E, Phillips S: Canadian best practice recommendations for stroke care (updated 2008). CMAJ 2008;179:S1–S125.
18.
Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr: Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945–2948.
19.
Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457–507.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.